Economic analysis of rituximab: In combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in portugal;Análise económica de rituximab: Em associação com ciclofosfamida, vincristina e prednisolona no tratamento de doentes com linfoma folicular avançado em portugal

Acta Medica Portuguesa

Volumn 23, Issue 6, 2010, Pages 1025-1034

  Braga, Paula ^a   Carvalho, Susana ^b   Gomes, Marília ^c   Guerra, Lurdes ^d   Paulo, Lúcio ^e   Marques, Herlander ^f   Negreiro, Filipa ^g   Pereira, Catarina ^h   Silva, Catarina ^g   Teixeira, Adriana ⁱ  

^a Roche Farmacêutica Química   (Portugal)

^b Instituto Portugues de Oncologia de Lisboa Francisco Gentil   (Portugal)

^c Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e Hospital Militar de Belem   (Portugal)

^f HOSPITAL DE BRAGA   (Portugal)

^g Eurotrials Consultores Científicos   (Portugal)

^h Departamento de Market Access and Health Economics   (Portugal)

ⁱ CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEATH; DISEASE COURSE; DRUG COST; FOLLICULAR LYMPHOMA; FOLLOW UP; LIFE EXPECTANCY; NONHODGKIN LYMPHOMA; PORTUGAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PORTUGAL; PREDNISOLONE; VINCRISTINE;

EID: 78751488553     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. World Health Organization: Globocan. http://www-depdb.iarc.fr/globocan [Acedido em 1 de Fevereiro de 2008]
2. GOLDMAN: Cecil Textbook of Medicine. W. B. Saunders Company, 21st ed 2000;964-8
3. MARCUS R, SWEETENHAM JW, WILLIAMS ME: Lymphoma: Pathology, Diagnosis and Treatment. Cambridge University Press 2007
4. FERLAY J, BRAY F, PISANI P, PARKIN DM: GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase. 2002
5. PFREUNDSCHUH M, TRUMPER L, KLOESS M et al: Twoweekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104(3):634-641
6. MILLER TP, DAHLBERG S, CASSADY JR et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade Non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-26
7. PORTLOCK CS, QIN J, SCHAINDLIN P et al: The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Ann Oncol 2004;15(10):1495-503
8. HOERR AL, GAO F, HIDALGO J, et al: Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004;22(22):4561-6
9. COIFFIER B: Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma. Semin Oncol 2004;31(1 Suppl 2):7-11
10. COIFFIER B, LEPAGE E, BRIERE J et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346:235-242
11. SEHN LH, DONALDSON J, CHHANABHI M et al: Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large-B-cell lymphoma (DLBC) in British Columbia (BC). Blood 2003;102:29a, abst
12. PETRYK M, GROSSBARD ML: Rituximab therapy of B-cell neoplasms. Clin Lymphoma 2000;1:186-94
13. PAN DC, PORTLOCK CS: Rituximab: Principles and practice of oncology 2003;17:2-15
14. VOSE J: Antibody therapy for non-Hodgkin's lymphoma. Clinical Oncology 1999;2:1-11
15. MARCUS R, IMRIE K, BELCH A et al: An international multicentre, randomized, open-label phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin's lymphoma. Blood 2003;102(11):28a, abst
16. MARCUS R, IMRIE K, BELCH A et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105(4):1417-23
17. Human Mortality Database: Disponível em www.mortality.org [Acedido em 1 de Fevereiro 2008]
18. Scotland and Newcastle Lymphoma Group: Database analysis commissioned by Roche; 2004
19. EDELMAN MJ, MEYERS FJ, SIEGEL D: The utility of follow- up testing after curative cancer therapy. A critical review and economic analysis. J Gen Intern Med 1997;12:318-331
20. DAVIES J: Western Infirmary, Edinburgh: interview 2004;5 Jul
21. WAHL R, KAMINSKI M, ZELENETZ A et al: Each subsequent therapy results in diminishing response rate and duration of response in low grade or transformed low grade non-Hodgkin's lymphoma. ASCO 2001;20:292a, abst
22. INFARMED: Orientações metodológicas para estudos de avaliação económica de medicamentos. Lisboa, 1999.
23. Diário da República, primeira série - N.°16, Portaria n.° 110- A/2007, de 23 de Janeiro de 2007
24. Ministério da Saúde: Contabilidade Analítica 2005, Hospitais do SNS. Ministério da Saúde, IGIF. Edição 2006
25. INFARMED http://www.infarmed.pt/formulario/index.html [Acedido em 13 de Fevereiro de 2008]
26. National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal: London: NICE, 2008. Disponível em http://www.nice.org.uk/aboutnice/howwework/devnicetech/ technologyappraisalprocessguides/guidetothemethodsoftechnologyappraisal.jsp [Acedido em 13 de Fevereiro de 2008]
27. FORSTPOINTNER R, DREYLING M, REPP R et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104(10):3064-71
28. COIFFIER B, LEPAGE E, BRIèRE J et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242
29. JOST LM, JERMANN M, STAHEL RA et al: Rituximab- EPOCH: an effective salvage regimen for relapsed, refractory or transformed B-cell lymphoma. Results of a phase II study. ASCO 2001;202:90a,abst
30. KNIGHT C, HIND D, BREWER N, ABBOTT V: Rituximab (MabThera®) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess 2004; 8(37):1-96
31. BERTO P, MORSANUTTO A, LOPATRIELLO S et al: Analisi costo-efficacia di rituximab + CHOP versus CHOP in soggetti affetti da linforma non-Hodgkin aggressivo, summary in English - Pharmacoeconomics - Italian Research Articles 2004;6(3):151-160
32. GROOT MT, LUGTENBURG PJ, HORNBERGER J, HUIJGENS PC, UYL-DE GROOT CA: Cost-effectiveness of rituximab (MabThera®) in diffuse large B-cell lymphoma (DLBCL) in the Netherlands. Eur J Hematol 2005;74:194-202
33. BEST J, HORNBERGER J, PROCTOR SJ et al: Cost-effectiveness analysis of rituximab combined with CHOP for treatment of diffuse large B-Cell lymphoma. Value in Health 2005;8:462-470